ID   U-CH17M
AC   CVCL_VR43
DR   ATCC; CRL-3402
DR   GEO; GSM2585630
DR   GEO; GSM2585631
DR   GEO; GSM2585632
DR   Wikidata; Q98133715
RX   PubMed=29148152;
WW   https://www.chordomafoundation.org/researchers/disease-models/u-ch17m/
CC   Doubling time: 3-10 days (PubMed=29148152); ~8-10 days (ATCC=CRL-3402); 6-8 days (Chordoma Foundation).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous or homozygous (PubMed=29148152).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Soft tissue; UBERON=UBERON_0034929.
ST   Source(s): ATCC=CRL-3402; PubMed=29148152
ST   Amelogenin: X,Y
ST   CSF1PO: 12,14
ST   D13S317: 11
ST   D16S539: 9,13 (PubMed=29148152)
ST   D16S539: 13 (ATCC=CRL-3402)
ST   D18S51: 12
ST   D3S1358: 16,18
ST   D5S818: 12
ST   D7S820: 9,12
ST   D8S1179: 9.2,12
ST   Penta D: 12,15
ST   Penta E: 11,14
ST   TH01: 7,9.3 (PubMed=29148152)
ST   TH01: 9.3 (ATCC=CRL-3402)
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C129927; Sacral chordoma
DI   ORDO; Orphanet_178; Chordoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VR44 ! U-CH17P
OI   CVCL_B6R8 ! U-CH17PII
OI   CVCL_VR45 ! U-CH17S
SX   Male
AG   38Y
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 19-12-24; Version: 11
//
RX   PubMed=29148152; DOI=10.1002/ijc.31161;
RA   Jager D., Lechel A., Tharehalli U., Seeling C., Moller P.,
RA   Barth T.F.E., Mellert K.;
RT   "U-CH17P, -M and -S, a new cell culture system for tumor diversity and
RT   progression in chordoma.";
RL   Int. J. Cancer 142:1369-1378(2018).
//